FDA to require new warning of secondary cancer risk for CAR-T cancer therapies
The Food and Drug Administration (FDA) is requiring a boxed warning on all existing CAR-T cancer treatments following a review of reports that the therapies themselves can increase the risk for some secondary cancers. In letters to the manufacturers of all six currently available CAR-T therapies…
#fda #breyanzi #bristolmyerssquibb #johnsonjohnson #legendbiotech #novartis #tecartus #yescarta #gilead